Following a successful pilot EQA scheme, the RfB is expanding its external quality assurance portfolio and will in future offer the Diabetes Autoantibodies (DiabAK) EQA scheme twice a year.
Measurable analytes:
- anti-ICA (islet cell antibodies)
- anti-glutamate decarboxylase (GAD)
- anti-tyrosine phosphatase (IA2)
- anti-zinc transporter 8 (ZnT8A)
- anti-insulin (IAA)
Registration is via your participant account at www.rfb.bio.
Registration deadline: August 3, 2026
Sample dispatch: October 13, 2026
Test period: October 19, 2026 – October 30, 2026
We look forward to your participation!
Your RfB Team
